Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: gleevec + web + 0.25  Related to the article below (Last Update: 8/5/2008)

Breast cancer: What you need to know
Food Consumer, IL -
... refracta that inhibits in vitro breast cells, an action that mimics the one of Gleevec, a drug for the treatment of chronic myoloid leukemia. ...
Marathon training a challenge to body, mind
Edison Sentinel, NJ - Jul 29, 2008
Over the last 20 years, the funds have contributed to advances in blood cancer treatments, including the drug Gleevec, for the treatment of patients with ...

NewsOK.com (subscription)
Researchers keep eyes on prize
NewsOK.com (subscription), OK - Jul 26, 2008
There are the inventors of cancer treatments like Gleevec. Anti-depressants like Paxil and Zoloft. And many other life-changing medications introduced in ...
Source: Google News

Absolute Bioavailability of Imatinib (Glivec?) Orally versus Intravenous Infusion -
B Peng, C Dutreix, G Mehring, MJ Hayes, M Ben-Am, … - The Journal of Clinical Pharmacology, 2004 - jcp.sagepub.com
... Imatinib capsules or oral solution was administered 2 hours after breakfast ... For the
iv administration, the time points were predose and 0.25, 0.5, 0.75, 1, 1.25 ...

Chronic Myeloproliferative Disorders The anticancer drug imatinib induces cellular autophagy -
A Ertmer, V Huber, S Gilch, T Yoshimori, V Erfle, J … - Leukemia, 2007 - nature.com
... access provided to Googlebot Access by Web Services. ... concentrations of imatinib varying
from 0.25 to 20 M ... Gleevec inhibits beta-amyloid production but not Notch ...

Evidence for the interaction of imatinib at the transport-substrate site (s) of the multidrug- … -
S Shukla, ZE Sauna, SV Ambudkar - Leukemia, 2007 - nature.com
Full text access provided to Googlebot Access by Web Services. ... (b) Imatinib stimulates
vanadate ... MgCl 2 for ABCG2) in the absence (lane 1) or presence of 0.25 mM ...

New Chronic Myelogenous Leukemia Guidelines Add Nilotinib CME
L Disclaimer - medscape.com
... for physicians; Family Physicians - up to 0.25 AAFP Prescribed ... are available on the
NCCN Web site. ... consider using nilotinib after any imatinib failure point in ...

Imatinib Mesylate Inhibits Platelet-Derived Growth Factor Receptor Phosphorylation of Melanoma Cells … -
EC Mcgary, A Onn, L Mills, A Heimberger, O Eton, … - Journal of Investigative Dermatology, 2004 - nature.com
... at 80% confluence for injection by a brief exposure to 0.25% trypsin and ... oral gavage
three times weekly (control group) and the other, imatinib mesylate (100 mg ...

A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal … -
D Mahadevan, L Cooke, C Riley, R Swart, B Simons, … - Oncogene, 2007 - nature.com
... Full text access provided to Googlebot Access by Web Services. ... to IM (0.05?50 M)
or MP470 (0.25?11 M ... Mechanisms of gleevec resistance in GIST and potential ...

Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach -
R Villuendas, JL Steegmann, M Pollan, L Tracey, A … - Leukemia, 2006 - nature.com
... Full text access provided to Googlebot Access by Web Services. ... described as being
associated with imatinib sensitivity (BTK ... MCyR at 12 months) (OR/0.25 units in ...

Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other … -
JC Hernandez-Boluda, F Cervantes - Drugs Today, 2002 - journals.prous.com
... derived growth factor receptor (2-5). In preclinical studies, imatinib was shown ...
inhibited cellular tyrosine phosphorylation by 50% (IC 50 ) being 0.25 ?M (6 ...

Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas … -
IF Pollack, RI Jakacki, SM Blaney, ML Hancock, MW … - Neuro-Oncology, 2007 - Duke Univ Press
... Similar articles in ISI Web of Science. ... made to administer these drugs at least 4
h before imatinib. ... to be 0.005, 0.010, 0.05, 0.10, 0.15, 0.20, 0.25, and 0.35 ...

Sensitivity and Resistance to Therapy Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity …
C Brendel, C Scharenberg, M Dohse, RW Robey, SE … - Leukemia, 2007 - nature.com
... access provided to Googlebot Access by Web Services. ... considerably lower levels
(0.07?0.25 M at ... penetration of imatinib mesylate (Gleevec): implications for ...
-

Source: Google Scholar

Gleevec, the targeted cancer pill, delivers more good news to patients

 

PORTLAND, Ore. – Gleevec, the targeted cancer pill that has saved more than 100,000 lives, now is saving more children with a dire leukemia, as well as preventing disease progression with long term use in adults with chronic myeloid leukemia.

“Data at this weekend’s meeting continues to show how much Gleevec has completely changed the outlook for so many, many patients facing cancer,” said Brian Druker, M.D., director of the OHSU Cancer Institute.

At the plenary session of the annual meeting of the American Society of Hematology researchers delivered news that Gleevec has been shown to improve outcomes for children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Ph+ ALL is the childhood leukemia with the worst prognosis and the Children’s Oncology Group study shows that adding Gleevec to the treatment almost completely reverses this poor prognosis. The Children’s Oncology Group is a worldwide clinical trial cooperative supported by the National Cancer Institute, a branch of the National Institutes of Health.

Also released at the conference is new data from the largest clinical trial in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) that showed Gleevec, with long-term use, can prevent progression to advanced stages of the disease.

Six-year results of the International Randomized Interferon versus STI571 (IRIS) study for which Druker served as principal investigator, demonstrated that continuous treatment with Gleevec produced a declining rate of relapse over time. The downward trend in the risk of disease progression while on Gleevec has continued since year two of the study. Remarkably, between years five and six, no patients progressed to an advanced phase of the disease.

“The news about Gleevec and the childhood leukemia study as well as the six-year IRIS study that shows there is no progression to advanced phase in CML means that more and more patients are surviving, despite being diagnosed with these cancers,” said Druker, JELD-WEN Chair of Leukemia Research, Howard Hughes Medical Institute Investigator and member of the National Academy of Sciences. He also is a professor of medicine (hematology and medical oncology), cell and developmental biology, and biochemistry and molecular biology in the OHSU School of Medicine.

Gleevec has also been approved for the treatment of gastrointestinal stromal tumors, pediatric CML, as well as five additional rare cancers.

###

Particulars: Michael Heinrich, M.D., professor of medicine (hematology/medical oncology) in the OHSU School of Medicine and the Portland Veteran’s Affairs medical Center, and a member of the OHSU Cancer Institute, has been the principal investigator in research studies involving GIST and Gleevec.

The OHSU Cancer Institute is the only National Cancer Institute-designated center between Sacramento and Seattle. It comprises some 120 clinical researchers, basic scientists and population scientists who work together to translate scientific discoveries into longer and better lives for cancer patients. In the lab, basic scientists examine cancer cells and normal cells to uncover molecular abnormalities that cause the disease. This basic science informs more than 200 clinical trials conducted at the OHSU Cancer Institute.

Contact: Christine Decker, 503 494-8231; deckerch@ohsu.edu for interview opportunities with Brian Druker, M.D., co-developer of Gleevec with Novartis Pharmaceuticals.

 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.